Rachel McMinn Biography and Net Worth

CEO of Neurogene

Rachel McMinn, Ph.D., is Chief Executive Officer of Neurogene and serves as Executive Chair of the company’s Board of Directors. She founded Neurogene in January 2018 with the mission of developing genetic medicines to improve the lives of neurologically-impaired people and their families. Prior to founding Neurogene, she served as the Chief Business and Strategy Officer of Intercept Pharmaceuticals, a company dedicated to patients with serious liver disease. Prior to her industry experience, Dr. McMinn was an award-winning biotechnology analyst, with 13 years of experience at firms including Bank of America Merrill Lynch, Cowen, and Piper Jaffray. She graduated from Cornell University magna cum laude with a B.A. and earned her Ph.D. from The Scripps Research Institute and was awarded a Post-Doctoral Miller Fellowship at the University of California, Berkeley.

What is Rachel McMinn's net worth?: The estimated net worth of Rachel McMinn is at least $27.46 million as of November 22nd, 2024. Dr. McMinn owns 1,297,859 shares of Neurogene stock worth more than $27,462,696 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. McMinn may own. Additionally, Dr. McMinn receives a salary of $676,540.00 as CEO at Neurogene. Learn More about Rachel McMinn's net worth.
How old is Rachel McMinn?: Dr. McMinn is currently 51 years old. There are 4 older executives and no younger executives at Neurogene. Learn More on Rachel McMinn's age.
What is Rachel McMinn's salary?: As the CEO of Neurogene Inc., Dr. McMinn earns $676,540.00 per year. Learn More on Rachel McMinn's salary.
How do I contact Rachel McMinn?: The corporate mailing address for Dr. McMinn and other Neurogene executives is 535 W 24th Street, 5th Floor, New York, NY 10011, United States. Neurogene can also be reached via phone at (877) 237-5020 and via email at [email protected]. Learn More on Rachel McMinn's contact information.
Has Rachel McMinn been buying or selling shares of Neurogene?: Rachel McMinn has not been actively trading shares of Neurogene during the last ninety days. Most recently, on Friday, November 22nd, Rachel Mcminn bought 47,500 shares of Neurogene stock. The stock was acquired at an average cost of $20.40 per share, with a total value of $969,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,297,859 shares of the company's stock, valued at $26,476,323.60. Learn More on Rachel McMinn's trading history.
Who are Neurogene's active insiders?: Neurogene's insider roster includes Stuart Cobb (Chief Scientific Officer), and Rachel McMinn (CEO). Learn More on Neurogene's active insiders.
Are insiders buying or selling shares of Neurogene?: In the last year, insiders at the sold shares 2 times. They sold a total of 11,298 shares worth more than $179,221.49. The most recent insider tranaction occured on May, 14th when insider Stuart Cobb sold 6,797 shares worth more than $102,974.55. Insiders at Neurogene own 11.6% of the company. Learn More about insider trades at Neurogene.
Information on this page was last updated on 5/14/2025.

Rachel McMinn Insider Trading History at Neurogene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/22/2024	Buy	47,500	$20.40	$969,000.00	1,297,859

Rachel McMinn Buying and Selling Activity at Neurogene

Neurogene Company Overview

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Today's Range

Now: $21.16

$19.88

$23.00

50 Day Range

MA: $26.02

$17.33

$34.37

2 Week Range

Now: $21.16

$6.88

$37.27

Volume

450,545 shs

Average Volume

219,681 shs

Market Capitalization

$327.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62

Rachel McMinn Biography and Net Worth

What is Rachel McMinn's net worth?

How old is Rachel McMinn?

What is Rachel McMinn's salary?

How do I contact Rachel McMinn?

Has Rachel McMinn been buying or selling shares of Neurogene?

Who are Neurogene's active insiders?

Are insiders buying or selling shares of Neurogene?